These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20431292)

  • 1. Modulation of eicosanoid production and activity as a potential explanation for some of the pleiotropic effects of statins.
    Birnbaum Y; Ye Y; Farmer J
    Cardiology; 2010; 116(1):45-7. PubMed ID: 20431292
    [No Abstract]   [Full Text] [Related]  

  • 2. Pleiotropic effects of statins and beyond.
    Lansberg P
    Cardiology; 2009; 112(1):1-3. PubMed ID: 18577879
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipids, statins and cardiovascular disease.
    Cheifitz R
    Climacteric; 2008 Aug; 11(4):347-8; author reply 348-50. PubMed ID: 18645702
    [No Abstract]   [Full Text] [Related]  

  • 4. Questioning the benefits of statins.
    Mazowita G
    CMAJ; 2005 Nov; 173(10):1210; author reply 1210. PubMed ID: 16275979
    [No Abstract]   [Full Text] [Related]  

  • 5. [Preadmission use of statins as treatment for strokes].
    González-Hernández A; López-Fernández JC; Fabre-Pi O; Cubero A
    Rev Neurol; 2007 Dec 1-15; 45(11):702-3. PubMed ID: 18050107
    [No Abstract]   [Full Text] [Related]  

  • 6. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
    Paumelle R; Staels B
    Trends Cardiovasc Med; 2008 Apr; 18(3):73-8. PubMed ID: 18436144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 8. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questioning the benefits of statins.
    Vos E; Rose CP
    CMAJ; 2005 Nov; 173(10):1207; author reply 1210. PubMed ID: 16275976
    [No Abstract]   [Full Text] [Related]  

  • 11. Pleiotropic effects and cholesterol-lowering therapy.
    Shaw SM; Fildes JE; Yonan N; Williams SG
    Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. At which stage of chronic kidney disease should dyslipidemia be treated?
    Krane V; Wanner C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):176-7. PubMed ID: 16932418
    [No Abstract]   [Full Text] [Related]  

  • 13. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentials and pitfalls of meta-analysis on statins.
    Lotrionte M; Agostoni P; Biondi-Zoccai GG
    Am J Med; 2008 Jan; 121(1):e3; author reply e5. PubMed ID: 18187058
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary prevention: dyslipidaemia.
    Pignone M
    Clin Evid; 2005 Dec; (14):142-50. PubMed ID: 16620402
    [No Abstract]   [Full Text] [Related]  

  • 16. [Statins and brain protection mechanisms].
    Tapia-Perez H; Sanchez-Aguilar M; Torres-Corzo J; Rodriguez-Leyva I; Herrera-Gonzalez LB
    Rev Neurol; 2007 Sep 16-30; 45(6):359-64. PubMed ID: 17899518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of statins in managing diabetic dyslipidemia.
    Toth PP
    J Fam Pract; 2010 May; 59(5 Suppl):S23-9. PubMed ID: 20544054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins in patients with chronic kidney disease: a double-edged sword?
    Kassimatis TI; Konstantinopoulos PA
    J Am Coll Cardiol; 2008 Nov; 52(20):1679; author reply 1680. PubMed ID: 18992660
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates.
    Dominiczak M
    Curr Opin Lipidol; 2009 Feb; 20(1):79-81. PubMed ID: 19106712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.